Use of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: a single-center experience

Basit Öğe Kaydı
dc.authoridGülsün Tezcan Karasu / 0000-0001-5700-5919
dc.authorscopusidGülsün Tezcan Karasu / 56382958800
dc.authorwosidGülsün Tezcan Karasu / IAF-9902-2023
dc.contributor.authorUygun, Vedat
dc.contributor.authorTezcan Karasu, Gülsün
dc.contributor.authorDaloğlu, Hayriye
dc.contributor.authorÖztürkmen, Seda
dc.contributor.authorYalçın, Koray
dc.contributor.authorÇelen, Safiye Suna
dc.contributor.authorYeşilipek, Akif
dc.date.accessioned2020-10-20T09:58:31Z
dc.date.available2020-10-20T09:58:31Z
dc.date.issued2020en_US
dc.departmentİstinye Üniversitesi, Hastaneen_US
dc.description.abstractAlthough advancements have been made in monitoring and preventing viral infections in HSCT patients, CMV reactivation still remains a critical post-transplant complication. Adoptive cell therapy is an alternative to pharmacotherapy of CMV infection in refractory patients. We retrospectively reviewed CMV infection cases after allogeneic HSCT who received U-DLI as treatment. In total, five pediatric patients between the ages of 0.5-16 years that received U-DLI for a post-HSCT CMV infection were evaluated. The dose of CD3+ lymphocytes administered in DLI was 5 × 104 /kg, except in one patient transplanted from his sibling. One patient, who was transplanted from an unrelated donor, received U-DLI from his haploidentical mother. CMV titers dramatically reduced after U-DLI. If the availability of CMV-specific CTL is an issue, we propose that one should consider using the U-DLI therapy with low cell dose from a seropositive donor. In case the stem cell donor is seronegative and a seropositive donor is unavailable, using the U-DLI therapy from seropositive, haploidentical donors is a promising way of treatment. More studies need to be conducted to further confirm the safety and efficacy of this treatment procedure.en_US
dc.identifier.citationUygun, V., Karasu, G., Daloğlu, H., Öztürkmen, S., Yalçın, K., Çelen, S. S., & Yeşilipek, A. (2020). Use of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: A single-center experience. Pediatric transplantation, e13882. Advance online publication. https://doi.org/10.1111/petr.13882en_US
dc.identifier.doi10.1111/petr.13882en_US
dc.identifier.pmid33073505en_US
dc.identifier.scopus2-s2.0-85092673666en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1111/petr.13882
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1148
dc.identifier.wosWOS:000579223100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTezcan Karasu, Gülsün
dc.language.isoenen_US
dc.relation.ispartofPediatr Transplanten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCytomegalovirusen_US
dc.subjectDonor Lymphocyte Infusionen_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.titleUse of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: a single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
petr.13882.pdf
Boyut:
395.87 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu